234 related articles for article (PubMed ID: 26451085)
21. Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.
Gallicchio R; Mastrangelo PA; Nardelli A; Mainenti PP; Colasurdo AP; Landriscina M; Guglielmi G; Storto G
Tumori; 2019 Oct; 105(5):367-377. PubMed ID: 31096849
[TBL] [Abstract][Full Text] [Related]
22. Dynamic changes of bone metastasis predict bone-predominant status to benefit from radium-223 dichloride for patients with castration-resistant prostate cancer.
Hashimoto K; Miyoshi Y; Shindo T; Hori M; Tsuboi Y; Kobayashi K; Fukuta F; Tanaka T; Miyamoto S; Maehana T; Okada M; Nishiyama N; Yanase M; Kato R; Hotta H; Kunishima Y; Takahashi A; Hinotsu S; Sakata KI; Kitamura H; Uemura H; Masumori N
Cancer Med; 2020 Nov; 9(22):8579-8588. PubMed ID: 32964674
[TBL] [Abstract][Full Text] [Related]
23. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
Li J; Armstrong AJ
Clin Adv Hematol Oncol; 2015 May; 13(5):293-8. PubMed ID: 26352773
[No Abstract] [Full Text] [Related]
24. Single-centre Experience of Use of Radium 223 with Clinical Outcomes Based on Number of Cycles and Bone Marrow Toxicity.
Dadhania S; Alonzi R; Douglas S; Gogbashian A; Hughes R; Dalili D; Vasdev N; Adshead J; Lane T; Westbury C; Anyamene N; Ostler P; Hoskin P; Sharma A
Anticancer Res; 2018 Sep; 38(9):5423-5427. PubMed ID: 30194198
[TBL] [Abstract][Full Text] [Related]
25. New radiopharmaceutical agents for the treatment of castration-resistant prostate cancer.
Maffioli L; Florimonte L; Costa DC; Correia Castanheira J; Grana C; Luster M; Bodei L; Chinol M
Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):420-38. PubMed ID: 26222274
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy plus estramustine for management of castration-resistant prostate cancer: meta-analysis of randomized controlled trials.
Zhang C; Jing T; Wang F; Gao X; Xu C; Sun Y
Actas Urol Esp; 2014 Apr; 38(3):184-91. PubMed ID: 24507454
[TBL] [Abstract][Full Text] [Related]
27. Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment.
Uemura H; Matsubara N; Kimura G; Yamaguchi A; Ledesma DA; DiBonaventura M; Mohamed AF; Basurto E; McKinnon I; Wang E; Concialdi K; Narimatsu A; Aitoku Y
BMC Urol; 2016 Nov; 16(1):63. PubMed ID: 27814714
[TBL] [Abstract][Full Text] [Related]
28. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
Basch E; Autio K; Ryan CJ; Mulders P; Shore N; Kheoh T; Fizazi K; Logothetis CJ; Rathkopf D; Smith MR; Mainwaring PN; Hao Y; Griffin T; Li S; Meyers ML; Molina A; Cleeland C
Lancet Oncol; 2013 Nov; 14(12):1193-9. PubMed ID: 24075621
[TBL] [Abstract][Full Text] [Related]
29. A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer.
Qi P; Chen M; Zhang LX; Song RX; He ZH; Wang ZP
PLoS One; 2015; 10(7):e0133803. PubMed ID: 26192308
[TBL] [Abstract][Full Text] [Related]
30. Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?
Serretta V; Valerio MR; Costa R; Tripoli V; Murabito A; Princiotta A; Scalici Gesolfo C; Borsellino N; Verderame F; Gebbia V; Licari M; Sanfilippo C;
Urol Oncol; 2019 Dec; 37(12):964-969. PubMed ID: 31601517
[TBL] [Abstract][Full Text] [Related]
31. Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?
Howard LE; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Divers CH; Valderrama A; Freedland SJ
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):380-384. PubMed ID: 27377207
[TBL] [Abstract][Full Text] [Related]
32. Impact of symptomatic skeletal events on health-care resource utilization and quality of life among patients with castration-resistant prostate cancer and bone metastases.
McKay R; Haider B; Duh MS; Valderrama A; Nakabayashi M; Fiorillo M; Ristovska L; Wen L; Kantoff P
Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):276-282. PubMed ID: 28220804
[TBL] [Abstract][Full Text] [Related]
33. [Bone and calcium metabolism associated with malignancy. Treatment of radium-223 dichloride for bone metastasis in castration resistant prostate cancer patients.].
Uemura H
Clin Calcium; 2018; 28(11):1485-1493. PubMed ID: 30374005
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: A systematic review and meta-analysis.
Qin Z; Li X; Zhang J; Tang J; Han P; Xu Z; Yu Y; Yang C; Wang C; Xu T; Xu Z; Zou Q
Medicine (Baltimore); 2016 Sep; 95(39):e4801. PubMed ID: 27684806
[TBL] [Abstract][Full Text] [Related]
35. Radium-223 in Metastatic Castration-Resistant Prostate Cancer: Clinical Development and Use in Contemporary Practice.
Morgan SC
J Med Imaging Radiat Sci; 2019 Dec; 50(4S1):S26-S30. PubMed ID: 31231006
[TBL] [Abstract][Full Text] [Related]
36. Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter database.
Keizman D; Fosboel MO; Reichegger H; Peer A; Rosenbaum E; Desax MC; Neiman V; Petersen PM; Mueller J; Cathomas R; Gottfried M; Dresler H; Sarid D; Mermershtain W; Rouvinov K; Mortensen J; Gillessen S; Daugaard G; Omlin A
Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):289-293. PubMed ID: 28244493
[TBL] [Abstract][Full Text] [Related]
37. Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: A tertiary academic center experience.
Afshar M; Evison F; James ND; Patel P
Urol Oncol; 2015 Aug; 33(8):338.e1-7. PubMed ID: 26059077
[TBL] [Abstract][Full Text] [Related]
38. A Retrospective Analysis of the First 41 mCRPC Patients with Bone Pain Treated with Radium-223 at the National Institute of Oncology in Hungary.
Küronya Z; Sinkovics I; Ágoston P; Bíró K; Bodrogi I; Böde I; Dank M; Gyergyay F; Vajdics T; Kolonics Z; Nagyiványi K; Rúzsa Á; Géczi L
Pathol Oncol Res; 2017 Oct; 23(4):777-783. PubMed ID: 28074331
[TBL] [Abstract][Full Text] [Related]
39. Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer-A Single Institution Experience.
Kairemo K; Milton DR; Etchebehere E; Rohren EM; Macapinlac HA
Curr Radiopharm; 2018; 11(2):147-152. PubMed ID: 29956640
[TBL] [Abstract][Full Text] [Related]
40. Practical guide to the use of radium 223 dichloride.
Den RB; Doyle LA; Knudsen KE
Can J Urol; 2014 Apr; 21(2 Supp 1):70-6. PubMed ID: 24775727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
